# Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andreas Stallmach,C. Langbein,Raja Atreya,Tony Bruns,Axel Dignaß,K Ende,Jochen Hampe,Franz Hartmann,Markus F. Neurath,Jochen Maul,J. Preiß,Renate Schmelz,Britta Siegmund,H Schulze,Niels Teich,Ulrike von Arnim,Daniel C. Baumgart,Carsten Schmidt |
| Citations | 164 |
| DOI | 10.1111/apt.13813 |
| Fields | Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.13813 |
| OpenAlex ID | https://openalex.org/W2529617706 |
| PMID | 27714831 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Andreas Stallmach](https://scholariq.org/researchers/andreas-stallmach/)
- [Ulrike von Arnim](https://scholariq.org/researchers/ulrike-von-arnim/)
- [Niels Teich](https://scholariq.org/researchers/niels-teich/)
- [Renate Schmelz](https://scholariq.org/researchers/renate-schmelz/)

## Paper journal

- [Alimentary Pharmacology & Therapeutics](https://scholariq.org/journals/alimentary-pharmacology-and-therapeutics/)

## Paper primary topic

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)

## Paper topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.